Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMP301 in recurrent low-grade serous ovarian cancer
2023-508204-38-00Phase 3Authorised
- Sponsor
- Verastem Oncology
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC), fallopian tube serous adenocarcinoma (FTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)fallopian tube serous adenocarcinoma (FTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-508204-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508204-38-00.